A Clinical Trial in Advanced Cutaneous Melanoma and Advanced Mucosal Melanoma
What is ARTISTRY-6?
ARTISTRY-6 is a research study for adult patients with advanced cutaneous melanoma or advanced mucosal melanoma that is inoperable or has spread, and who have received prior treatment with an anti-programmed death-ligand 1 (anti-PD(L)1) therapy.
This study is testing an investigational treatment called nemvaleukin alfa (nemvaleukin). Nemvaleukin is investigational and not approved by any regulatory authority. It is not known if nemvaleukin is safe or effective.
ARTISTRY-6 is being funded by the pharmaceutical company Alkermes.
Quick Facts about ARTISTRY-6
More information is provided below, and additional details can be located using the navigation at the top of this page.
Open Label Study
Both the participant and doctor will know what treatment the participant is receiving.
All participants will receive the study drug nemvaleukin via an intravenous (IV, meaning through the veins) infusion. Participants will receive treatment at their doctor’s office or cancer center.
To learn more about the ARTISTRY-6 study, click the link below to access study information on the National Institutes of Health website, www.clinicaltrials.gov.
ARTISTRY-6: What Treatment Will a Participant Receive?
ARTISTRY-6 is enrolling participants in two different treatment groups based on the type of cancer. All participants will receive the study drug, nemvaleukin. Both groups will receive nemvaleukin via an intravenous (or IV, meaning through the veins) infusion. The treatment groups are listed below:
Cutaneous Melanoma Group
Mucosal Melanoma Group
What is Nemvaleukin?
Nemvaleukin is an investigational treatment that is currently being evaluated in studies of advanced cancers. Nemvaleukin is not approved by any regulatory authority.
Nemvaleukin is a modified molecule that binds to a protein known as the interleukin-2 (IL-2) receptor and has the potential to stimulate the body’s immune system which may help fight certain types of cancers. Nemvaleukin is given intravenously (through the veins) as a 30-minute infusion in this study.